AstraZeneca (AZN) Financial Analysis & Valuation | Quarter Chart
AstraZeneca (AZN)
AZNPrice: $190.95
Fair Value: 🔒
🔒score
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lok... more
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, an... more
Description
Shares
| Market Cap | $296.14B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | GB | CEO | Pascal Claude Roland Soriot |
| IPO Date | 1993-05-12 | CAGR | 0.06% |
| Employees | 94,300 | Website | www.astrazeneca.com |
| Div. Yield | 1.63% | Payout Ratio | 0.47% |
| Buy Back Yield | 0.07% | Total Yield | 1.7% |
AZN chart loading...
Fundamentals
Technicals
| Enterprise Value | $337.93B | P/E Ratio | 20.62 |
| Forward P/E | 23.74 | PEG Ratio | 5.43 |
| P/S Ratio | 5.01 | P/B Ratio | 6.44 |
| P/CF Ratio | 21.43 | P/FCF Ratio | 34.73 |
| EPS | $9.26 | EPS Growth 1Y | 33.07% |
| EPS Growth 3Y | 119.87% | EPS Growth 5Y | 119.14% |
| Revenue Growth 1Y | 9.93% | Gross Margin | 0.8% |
| Operating Margin | 0.24% | Profit Margin | 0.17% |
| ROE | 0.22% | ROA | 0.09% |
| ROCE | 0.18% | Current Ratio | 0.91 |
| Quick Ratio | 0.71 | Cash Ratio | 0.23 |
| Debt/Equity | 0.72 | Interest Coverage | 8.54 |
| Altman Z Score | 3.71 | Piotroski Score | 8 |